ResMed (RMD) Reports In-Line Q3 EPS

Go back to ResMed (RMD) Reports In-Line Q3 EPS

Goldman Sachs Downgrades ResMed (RMD) to Neutral

April 27, 2015 8:18 AM EDT

Goldman Sachs downgraded ResMed (NYSE: RMD) from Buy to Neutral.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $65.70 yesterday.

... More